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Paediatric populations have been identified as desirable end-users of microneedle technology. 
Aim 
The aim of this literature review was to examine published research which explores the perceptions 
and acceptability of microneedle technology in both patients and HCPs.  
Methods 
A series of keywords and their synonyms were combined in various combinations and permutations 
using Boolean operators to sequentially search four databases (PubMed, Web of Science, EMBASE and 
CINAHL). Following removal of duplications and irrelevant results, 12 research articles were included 
in the final literature review. 
Results 
The opinions of patients, parents, children and HCPs were collated. A positive perception and a high 
level of acceptability predominated. 
Conclusion 
Microneedle technology research has been focussed on demonstrating efficacy with minimal focus on 
determining HCP/public perception and acceptability for paediatric use, exemplified by the paucity of 
studies presented in this review. Commercial viability will depend on HCP/public acceptability of 
microneedle technology. An effort must be made to identify the barriers to acceptance and to 











Since its invention in 1853 (1, 2), the hypodermic needle has become the most widely used medical 
device (3), with an estimated 16 billion injections administered worldwide (4). This form of 
administration permits rapid delivery of plasma levels, careful titration of narrow therapeutic index 
drugs and administration of those exhibiting poor oral bioavailability by avoiding first pass metabolism 
and the degradative environment of the enteral system. Despite efficacy and widespread use, 
conventional hypo-dermic needles are associated with hazardous waste, accidental needle-stick, 
nosocomial infection as well as phobias, pain and significant anxiety in both adult and paediatric 
populations alike (3, 5-7). Guided by these concerns, research has been focused on the development 
of alternate drug delivery methods. One such method that has emerged is delivery via microneedle 
technology. Microneedles are designed specifically to target the outermost, rate-limiting, skin barrier 
layer, the stratum corneum, creating transient pathways for transcutaneous delivery (8). It is reported 
that microneedles can facilitate drug delivery through stratum corneum interruption without 
stimulating the pain receptors or blood vessels that lie beneath (9) thus being perceived as completely 
painless and devoid of bleeding. This technology has been used in a wide variety of pharmaceutical 
applications including the delivery of drugs (10-13) and macromolecules, namely vaccines, proteins 
and peptides (14-25). The major microneedle approaches employed in order to achieve facilitated 
delivery are solid, coated, hollow, dissolvable and swellable devices (26). Solid microneedles are 
primarily used for skin pre-treatment (22), whereby the needles puncture the skin, temporarily 
increasing permeability. This facilitates the passive diffusion of drug from a reservoir, typically in the 
form of a patch (26). Coated microneedles pierce the stratum corneum, the drug layer dissolves and 
the active is deposited in the skin (22, 26). Dissolvable microneedles are polymer based; the drug is 
incorporated into the formulation and is released as the system dissolves (22, 26). Hollow 
microneedles facilitate drug diffusion (22), via a method of intradermal injection that is similar to that 
of conventional parenteral delivery. Finally swellable micro-needles rapidly take up interstitial fluid 
upon skin insertion to form continuous, unblockable, hydrogel conduits from attached patch-like drug 
reservoirs to the dermal microcirculation (27). In spite of promising results, the commercial success of 
microneedle technology will depend on end-user acceptability. Acceptability refers to determining 
how well an intervention will be received by the target population and the extent to which a new 
intervention or its components may meet the needs of the target population and organisational 
setting (28). Interventions can often be developed without sufficient understanding of how the target 
population will embrace its activities (28). A formulation with poor patient acceptability will affect 
compliance, prescribing practices and ultimately commercial viability (29) thus the European 
Medicines Agency (EMA) has recommended that acceptability studies form an integral component of 
pharmaceutical development. 
Aim 
The aim of this literature review was to examine published research which explores the perceptions 
and acceptability of microneedle technology in both patients and HCPs. A particular focus was placed 
on the amenability of this technology for use in the paediatric population, as children have been 













Keywords and their synonyms or related terms were chosen which define the important concepts of 
the search. These included ‘acceptability’; ‘acceptance’; ‘perception’; ‘microneedle’; ‘paediatric’; 
‘child’; ‘children’; ‘vaccination’; ‘immunisation’; ‘healthcare’; ‘public’; ‘parent’ and ‘guardian’. These 
keywords were combined in a variety of different permutations and combinations using the Boolean 
operators AND and OR. The same search was applied to four databases (PubMed; Web of Science; 
EMBASE and CINAHL), using Google as a search engine. No restrictions or advanced search filters were 
applied to the database searches. The search was repeatedly conducted from 6th October 2014 to 
16th January 2015.  
 
Results 
The initial search across the chosen databases yielded 61 results. Following removal of duplications; 
34 results remained. Table 1 summarises the inclusion and exclusion criteria applied by the author.  
Table 1 Literature search inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Related to the perception and acceptability of 
microneedle technology 
Published in English language 
Human subjects 
Not related to the perception and acceptability of 
microneedle technology 
Related only to microneedle  technology 
No abstract available 




Eleven of these results were excluded based on the irrelevance of their title and/or abstract. The 
remaining 23 results were assessed in full and their relevance to the query was determined. This 
process returned nine relevant results and revealed a further three results that had not been included 
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Figure 1 Literature search results 
Discussion 
The purpose of this review was to collate the literature which examined the perception and 
acceptability of microneedle technology for use in paediatrics. The literature search yielded 12 results 
directly related to the research query. Eight of the search results involved the actual administration of 
microneedle technology while the remaining four involved the hypothetical discussion of the 
technology. There are several methods to assess acceptability, both qualitative and quantitative. 
Popular and effective qualitative research methods include interviews and focus groups. These 
provide considerable opportunity for discussion between the researcher(s) and the target population. 
They also permit the researcher to probe topics as they emerge naturally in conversation, resulting in 
an in-depth understanding of forces that may impede or facilitate the intervention. During an 
interview, the interviewer engages an individual in a discussion about the proposed intervention. The 
individual may represent a member of the target population or an organisational representative with 
the experience to knowingly assess the acceptability of the intervention. Focus groups have been 
described as one of the most widely used qualitative research tools in the applied social sciences (28, 
30), useful for designing healthcare interventions, pre-testing intervention materials, and establishing 
acceptable intervention implementation procedures. Interview techniques were used in three of the 
research papers presented here (31-33) and focus group methods were used in a further three (9, 31, 
34). Focus groups are advantageous as they permit and facilitate a collective brainstorming, resulting 
in a “synergistic group effect” (28). In addition, focus groups are more cost effective in both time and 
resources. Quantitative research methods, to determine acceptability, were also used in several of 
the research papers presented here. The primary method of quantitative research was the use of 
questionnaires (8, 9, 32, 33, 35-40). Several of the papers employed previously validated 
questionnaires, for example Modified Theory of Reasoned Action (35), Vaccinees’ Perception of 
Injection (40) and McGill Pain Questionnaire-Short Form (8), while the remainder developed 
questionnaires for the purpose of their research. 
Perception and acceptability of microneedle technology 
Eleven of the studies reported a positive response to microneedles with only one study reporting the 
contrary (36). Several recurring themes emerged which appeared to positively guide acceptability. 
These included; a perceived or actual reduction in pain associated with microneedle technology (8, 9, 
31-35, 37-40); ease and convenience of administration (9, 32-35, 37-39); potential for self-
administration (9, 34, 35) and attractive visual appearance (9, 31, 34, 37, 39). Conversely, several 
barriers to acceptability were identified; unfamiliarity with the technology (9, 31, 34); allergic potential 
(31, 34) and the inclusion of the term ‘needle’ in the name of the product (34). Research and 
development, particularly for paediatric markets, should focus on these barriers and strive to remove 
them through patient education, the development of a hypoallergenic delivery system and the 
adoption of novel nomenclature e.g. ImmunPatch®, to eliminate the negative connotations associated 
with the term ‘needle’. 
It is also important to consider HCP acceptability of microneedles. It has been demonstrated that the 
majority of patients will reserve the ultimate healthcare decision for their HCP (31). Five of the papers 
presented in this literature review included the opinions of 711 HCPs (9, 32, 33, 38, 39). 90.65% 
(n=644) of those HCPs included declared a positive response to microneedle technology, with 76.37% 
(n=543) expressing preference for microneedle technology over conventional administration. 
Perceived benefits were similar to those mentioned by the general public, such as increased patient 
acceptability, especially in the needle-phobic (9, 38, 39) but HCPs acknowledged additional benefits 
such as improved immunogenicity and seroprotection (38, 39) and a reduced risk of needle-stick injury 
(9). However, several barriers to acceptability were acknowledged by HCP: risk of cross-contamination 
and an inability to ensure accurate delivery on microneedle application (9). Significant efforts have 
been made to address these concerns with devices based on biodegradable dissolving formulations 
receiving increased attention. Once inserted into the skin, these polymeric systems will either rapidly 
dissolve or undergo such morphological changes that disable effective skin penetration if applied to 
another individual (41, 42), thus preventing intentional or accidental cross contamination. An effort 
must be made to formulate the inclusion of a delivery indicator without significantly increasing the 
cost of production. 
Perception and acceptability for use in immunisation 
Vaccines are a key contributor to public health (43). Despite repeatedly demonstrating cost-
effectiveness, the WHO has estimated that vaccine spending accounts for only 2–3% of the total 
pharmaceutical market. Total costs of providing immunisation services are divided into capital and 
recurrent costs (44, 45). Capital costs are identified as items that last longer than one year and are 
therefore incurred every few years rather than annually. Important capital costs for immunisation 
services are associated with cold chain equipment vehicles. Recurrent costs are those items consumed 
during the year, warranting regular purchase. Recurrent costs include the vaccines themselves and 
training activities (44). In recent years, the global vaccine market has undergone rapid growth. The 
impetus for this changing status is a combination of improved profitability with the development of 
‘blockbuster vaccines’, defined as those with US sales of at least one billion dollars (46), such as Pfizer’s 
Prevnar7® and Prevnar 13®, GSK’s Rotarix® and MSD’s Rotateq®, new funding opportunities with 
government grants and public–private partner-ships (43), and new manufacturing techniques, namely 
microneedle technology. 
Vaccine delivery to the skin is a logical approach (26). The skin is an immunogenic organ, housing a 
high concentration of professional antigen presenting cells (47). This permits the induction of a strong 
immune response upon antigenic challenge (47). For this reason, microneedles are especially 
attractive for immunisation. They have demonstrated a compatibility with live, inactivated and 
subunit vaccines (12, 13), the ability to induce comparable and, in some cases, improved 
immunogenicity when compared to conventional vaccination (23-25, 48), coupled with significant 
dose sparing characteristics (25, 47). Microneedle-mediated vaccination could potentially reduce both 
the capital and recurrent costs associated with conventional immunisation programmes: their 
thermostability eliminates cold-chain transportation requirements (17, 20, 21) and their potential for 
self-administration could reduce the requirement for trained personnel to administer the vaccine. 
There are currently 12 clinical trials at various stages involving the delivery of vaccines using 
microneedle technology. Ten of these have been completed; one is actively recruiting, while the other 
has completed recruitment. Eleven of the 12 clinical trials involve vaccine delivery using hollow 
microneedles (Soluvia®, MicronJet®), while the remaining trial involves delivery using a dissolvable 
microneedle patch. Vaccine targets under trial include varicella zoster, polio and influenza (49). It is 
not possible to discuss vaccination without mentioning influenza. It is estimated that 5–10% of adults 
and 20–30% of children are infected with influenza globally per annum. Influenza vaccination is one 
of the most effective methods to prevent infection or complications from illness, providing 
approximately 70–90% protection against clinical disease in healthy adults aged 18–59, provided there 
is good correlation between the vaccine antigens and circulating viral strains (27). The requirement 
for re-vaccination on an annual basis as a result of viral antigenic shift and drift explains the popularity 
and commercial advantage of influenza vaccine development. This review presents the results of a 
first-in-humans study of microneedle patch acceptability for self-vaccination against influenza (35). In 
this study, etched, stain-less steel microneedles were mounted on adhesive foam backing. When this 
self-administered microneedle patch was offered to participants as an alternative to conventional 
vaccination, intent to vaccinate increased from 44% at baseline to 65%. This review also highlights the 
success of Intanza®, a trivalent, inactivated influenza vaccine that is delivered intradermally with the 
world’s first proprietary microinjection system, Soluvia®. This system features a 30 gauge hollow 
microneedle designed for perpendicular administration into the intradermal space. The microneedle 
is pre-attached to a delivery system that limits the depth of insertion to 1.5 mm from the skin’s surface. 
The needle is attached to a glass syringe prefilled with the vaccine dose and a needle shielding system 
that covers the needle post injection (50). The hollow microneedle within this system is 10–16 times 
shorter and 40% thinner than the conventional needles used for IM vaccinations (50). In addition, the 
microinjection system allows the precise administration of 0.1ml (50). The integrated needle-shielding 
system is manually activated immediately after vaccination, minimising the risk of needle-stick injury, 
contamination and illicit re-use (50). Comparable acceptability studies of Intanza® have been 
undertaken in European countries such as the United Kingdom, France, Germany, Belgium, Spain, 
Czech Republic and Turkey as well as Australia and Argentina, compiling the opinions of 13,518 
participants and 680 general physicians. Of the 10,740 adults that were vaccinated by Intanza®, 96.6% 
(95–98%) declared they were “satisfied” or “very satisfied” and 93.7% (85–99%) indicated that they 
would prefer to be vaccinated by this method, if given a future choice. The latter statistic is particularly 
significant as it provides an indication of potential uptake associated with microneedle-mediated 
influenza vaccination. Vaccination rates remain below the targeted coverage rate of 75% as 
recommended by the European Centre for Disease Prevention and Control. Many reasons have been 
hypothesised to explain this low vaccination uptake, including a low perception of risk, a general lack 
of accurate information about influenza and vaccination, a fear of possible side and perceived side 
effects and issues of cost, availability and convenience. This literature review has highlighted how 
microneedle technology using either a patch system (35) or  the microinjection system Soluvia®, has 
the ability to ameliorate several of these concerns, exemplified by the fact that 30% of previously 
unvaccinated participants were willing to be vaccinated when offered this technology (35). 
Perception and acceptability for use in paediatrics 
In their exploratory study, Birchall et al. captured the views of the eventual end-users of microneedle 
technology (9). Focus groups comprising members of the public and HCPs were convened. In all seven 
focus groups, microneedle technology was identified as being “good for children”. Questionnaires 
were further used to substantiate the outputs from the qualitative focus groups. This questionnaire 
revealed that 92% of public respondents agreed that microneedles would be ideal for the 
administration of medicines to children. Three of the papers presented in this review explored the use 
of microneedles in the paediatric population (31, 34, 36). One study explored children’s views on 
microneedle use as an alternative to blood sampling and reported a positive response (34). Similarly, 
a second study assessed the views parents of premature babies on microneedle-mediated monitoring 
as an alternative to blood sampling and once again reported a positive response (31). A third study 
explored parent’s attitudes toward multiple vaccinations at a single visit, with several alternate 
methods, including a microneedle device. This study reported that the microneedle device, 
MicronJet®, was not perceived as better than the conventional syringe (36). While this system is 
composed of four 0.6 mm hollow silicon microneedles, it is attached to a standard syringe barrel thus 
resembling a conventional vaccine system. This arrangement may explain the reduced acceptability 
reported in this study. Vaccination is one of the most common causes of iatrogenic pain in the 
paediatric population (51). This pain is a source of distress for children and their guardians and can 
lead to pre-procedural anxiety, needle phobia in later life, mistrust in HCPs and healthcare avoidance, 
including non-adherence with vaccination schedules (52). While several techniques have been 
employed with varying success to manage pain during paediatric injections (topical anaesthetic, music 
distraction, oral distraction in infants, positioning techniques and pH alteration), the ability of 
microneedles to eliminate pain on injection is a significantly desirable attribute (31). In Ireland, the 
Health Service Executive (HSE) recommends 15 vaccinations (16 for females), to be administered from 
birth to approximately 14 years of age. Current vaccination practices typically involve administration 
of two or three vaccines concomitantly at a single visit. Research has demonstrated that the most 
notable reason influencing a guardian’s comfort level with the maximum number of injections per visit 
for their child was avoiding too much pain and discomfort (53, 54). Therefore, there is a considerable 
commercial market for microneedle-mediated childhood immunisation. However, similar to other 
areas of medical research, the industry remains hesitant to invest in paediatric vaccines given the 
significant ethical implications associated with this special population. While the development of 
microneedle-mediated childhood vaccination programmes is a logical goal, microneedle technology 
could also be used in specific subgroups of the paediatric population to reduce treatment burden. For 
example, Gupta et al. concluded that insulin delivery using hollow micro-needles in children with Type 
1 diabetes was less painful and had a more rapid onset of action compared to conventional 
administration (14, 55). Similarly Norman et al. demonstrated that intradermal insulin delivery using 
a hollow microneedle device resulted in less insertion pain and faster onset and offset of action in 
children and adolescents, suggesting that this reduction in pain may improve compliance with insulin 
delivery (56). Therefore, while the benefits of microneedle technology are multi-fold, their dose 
sparing characteristics, thermostability and reduced potential for needle-stick, pale in comparison to 







The purpose of this review was to determine the perception and acceptability of microneedle 
technology. Research in recent years has focussed on successfully demonstrating the efficacy of the 
technology with minimal focus on determining acceptability, as demonstrated by this review. The 
benefits of microneedle technology in vaccination, especially in the paediatric population are glaringly 
apparent. However, commercial viability will depend on acceptability of this technology by the 
primary stakeholders: parents who will decide the vaccination method and HCPs who will decide the 
vaccination mode. Therefore, research ought to focus on increasing awareness of the technology and 
promoting education in these stakeholder groups. 
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